CLINICAL TRIALS PROFILE FOR WARFARIN POTASSIUM
✉ Email this page to a colleague
All Clinical Trials for warfarin potassium
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00311987 ↗ | Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients | Terminated | Johns Hopkins University | Phase 1/Phase 2 | 2006-04-01 | The natural thyroid hormones, thyroxine (T4) and triiodothyronine (T3), are known to have a cholesterol-lowering effect. Their pharmacologic use for this purpose is limited, however, by their actions on other organs, including the heart, bone, and brain, where there can be side effects of excessive thyroid hormone action. 3,5-diiodothyropropionic acid (DITPA) is a thyroid hormone analog with relative selectivity for a form of the thyroid hormone receptor expressed in the liver, where it regulates several aspects of lipid metabolism, including the clearance of low-density lipoprotein (LDL) cholesterol. This study is designed to determine whether DITPA is safe and effective in achieving LDL cholesterol levels that are consistent with the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines in patients who have not achieved those levels on conventional therapy, due to drug-resistant disease, drug intolerance, or both. This is a single-center, randomized, double-blind, placebo-controlled study. Following a 4-week Pre-Randomization Phase with dietary counseling and a 2-week placebo run-in, eligible patients will be randomized (1:1:1) to receive DITPA (90 mg/day, 180 mg/day), or placebo for a total treatment duration of 12 weeks. Sixty (60) patients will be randomized to 1 of 3 treatment groups in a 1:1:1 ratio (i.e., 20 patients per treatment group): - DITPA at 90 mg/day (45 mg twice a day [BID] taken orally) - DITPA at 180 mg/day (90 mg BID taken orally) - Placebo (BID taken orally) Those patients randomized to receive DITPA at 90 mg/day will receive 45 mg/day for the first 2 weeks, followed by 90 mg/day for 10 weeks. Those patients randomized to receive DITPA at 180 mg/day will receive 45 mg/day for the first 2 weeks, followed by 90 mg/day for the next 2 weeks, and then 180 mg/day for 8 weeks. |
| NCT00732966 ↗ | Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics? | Unknown status | Assaf-Harofeh Medical Center | N/A | 2008-09-01 | Most Angiotensin receptor blocker's (ARBs) are metabolized by cytochrome P4502C9 (CYP2C9), one of the major isoforms of the cytochrome P450 in human liver microsome. The purpose of this study is to evaluate whether CYP2C9 polymorphism has a significant clinical influence on the blood pressure lowering effect of losartan and valsartan. Weather there is a genetic importance in choosing the right ARB for the right patient. |
| NCT00829933 ↗ | Late Phase 2 Study of DU-176b in Patients With Non-Valvular Atrial Fibrillation | Completed | Daiichi Sankyo Co., Ltd. | Phase 2 | 2007-03-01 | The primary objective of this study is to compare the incidence of hemorrhagic events in patients treated for non-valvular atrial fibrillation with DU-176b at each dose level versus warfarin potassium (warfarin). The secondary objective includes between-group comparisons with regard to incidence of thromboembolic events, pharmacodynamic parameters, and biomarkers for the efficacy evaluation, as well as incidence of adverse events and adverse reaction for the safety evaluation. |
| NCT01510847 ↗ | The Effect of 90-day Oral Testosterone Therapy in Chinese Males With Type 2 Diabetes (T2DM) | Terminated | Duke-NUS Graduate Medical School | Phase 4 | 2011-10-01 | The study hypothesis is that treatment with oral Testosterone according to the study regimen will improve glycemic control in T2DM Chinese males in Singapore as indicated by a reduction in HbA1c levels at study day 90. |
| NCT01510847 ↗ | The Effect of 90-day Oral Testosterone Therapy in Chinese Males With Type 2 Diabetes (T2DM) | Terminated | Singapore General Hospital | Phase 4 | 2011-10-01 | The study hypothesis is that treatment with oral Testosterone according to the study regimen will improve glycemic control in T2DM Chinese males in Singapore as indicated by a reduction in HbA1c levels at study day 90. |
| NCT01510847 ↗ | The Effect of 90-day Oral Testosterone Therapy in Chinese Males With Type 2 Diabetes (T2DM) | Terminated | Singapore Clinical Research Institute | Phase 4 | 2011-10-01 | The study hypothesis is that treatment with oral Testosterone according to the study regimen will improve glycemic control in T2DM Chinese males in Singapore as indicated by a reduction in HbA1c levels at study day 90. |
| NCT03245307 ↗ | A Study To Test The Effect Of Apatinib On P450 Enzymes | Unknown status | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | 2017-08-22 | Apatinib, an oral inhibitor of vascular endothelial growth factor receptor 2（VEGFR-2）, inhibits multiple cytochrome P450 (CYP450) enzymes in vitro. This study in patients with advanced cancer evaluated the effect of Apatinib on CYP450 function by comparing the pharmacokinetics of CYP-specific probe drugs in the presence and absence of Apatinib. The probes used included Nifedipine (CYP3A specific), warfarin (CYP2C9 specific). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for warfarin potassium
Condition Name
| Condition Name for warfarin potassium | |
| Intervention | Trials |
| Assess the Effects of a the 90-day Oral TS Study Regimen on PSA, IPSS, Haemoglobin and Haematocrit, and to Assess Adverse and Serious Adverse Events. | 1 |
| Atrial Fibrillation | 1 |
| CTEPH | 1 |
| Cytochrome P450 Interaction | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for warfarin potassium
Trials by Country
Clinical Trial Progress for warfarin potassium
Clinical Trial Phase
Clinical Trial Sponsors for warfarin potassium
Sponsor Name
